Medicenna Therapeutics Corp Asset Resilience Ratio
Medicenna Therapeutics Corp asset resilience ratio. Medicenna Therapeutics Corp (MDNA) has an Asset Resilience Ratio of 81.24% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medicenna Therapeutics Corp (MDNA) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Medicenna Therapeutics Corp (2017–2025)
Asset resilience ratio of Medicenna Therapeutics Corp from 2017 to 2025. This chart shows how Medicenna Therapeutics Corp's Asset Resilience Ratio has changed over time. Read MDNA total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Medicenna Therapeutics Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Medicenna Therapeutics Corp.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$10.61 Million | 81.24% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$10.61 Million | 81.24% |
Asset Resilience Insights
- Very High Liquidity: Medicenna Therapeutics Corp maintains exceptional liquid asset reserves at 81.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Medicenna Therapeutics Corp Industry Peers by Asset Resilience Ratio
Compare Medicenna Therapeutics Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Medicenna Therapeutics Corp Asset Resilience Ratio by Year (2017–2025)
Medicenna Therapeutics Corp asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Medicenna Therapeutics Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 87.51% | CA$24.84 Million ≈ $17.97 Million |
CA$28.38 Million ≈ $20.53 Million |
-1.24pp |
| 2024-03-31 | 88.75% | CA$16.98 Million ≈ $12.28 Million |
CA$19.13 Million ≈ $13.84 Million |
-3.43pp |
| 2023-03-31 | 92.18% | CA$33.60 Million ≈ $24.30 Million |
CA$36.45 Million ≈ $26.36 Million |
+4.63pp |
| 2022-03-31 | 87.55% | CA$20.54 Million ≈ $14.85 Million |
CA$23.46 Million ≈ $16.97 Million |
-8.03pp |
| 2021-03-31 | 95.58% | CA$40.38 Million ≈ $29.21 Million |
CA$42.25 Million ≈ $30.56 Million |
-3.64pp |
| 2020-03-31 | 99.22% | CA$37.70 Million ≈ $27.27 Million |
CA$38.00 Million ≈ $27.49 Million |
+53.51pp |
| 2019-03-31 | 45.71% | CA$2.37 Million ≈ $1.72 Million |
CA$5.19 Million ≈ $3.75 Million |
-44.33pp |
| 2018-03-31 | 90.04% | CA$3.94 Million ≈ $2.85 Million |
CA$4.37 Million ≈ $3.16 Million |
-6.89pp |
| 2017-03-31 | 96.93% | CA$14.04 Million ≈ $10.15 Million |
CA$14.48 Million ≈ $10.48 Million |
-- |
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleuk… Read more